Mitral Regurgitation: A Comprehensive Review of Etiology, Pathophysiology, Management, and Emerging Therapies

Abstract

Mitral regurgitation (MR) is a prevalent valvular heart disease with significant implications for morbidity and mortality. This review aims to provide a comprehensive overview of MR, encompassing its diverse etiologies, intricate pathophysiology, advanced diagnostic modalities, nuanced staging, prognostic considerations, established and emerging therapeutic interventions, lifestyle management strategies, and promising advancements in drug therapies and alternative treatments. The report is targeted towards experts in the field, providing detailed insights and critical analyses of current challenges and future directions in MR management.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Mitral regurgitation (MR), characterized by the retrograde flow of blood from the left ventricle (LV) into the left atrium (LA) during systole, represents a significant burden on healthcare systems worldwide. Its prevalence increases with age, affecting a substantial proportion of the elderly population [1]. Untreated severe MR can lead to progressive LV dysfunction, heart failure, pulmonary hypertension, and increased risk of sudden cardiac death [2]. While surgical mitral valve repair or replacement has been the cornerstone of treatment for decades, the field is rapidly evolving with the development of less invasive percutaneous techniques and the exploration of novel pharmacological therapies. This review aims to provide a detailed and comprehensive examination of MR, addressing its complex pathophysiology, diagnostic challenges, current and emerging treatment strategies, and future directions in research.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Etiology and Classification of Mitral Regurgitation

MR can be broadly classified into two main categories: primary (organic) MR and secondary (functional) MR [3]. Primary MR results from intrinsic abnormalities of the mitral valve apparatus, including the leaflets, chordae tendineae, papillary muscles, or annulus. Secondary MR, on the other hand, is caused by LV remodeling and dysfunction, leading to geometric distortion of the mitral valve annulus and tethering of the leaflets, without primary structural abnormalities of the valve itself.

2.1 Primary Mitral Regurgitation

Common causes of primary MR include:

• Mitral Valve Prolapse (MVP): Myxomatous degeneration of the mitral valve leaflets, leading to leaflet billowing into the LA during systole, with or without chordal rupture. MVP is the most common cause of primary MR in developed countries [4].
• Rheumatic Heart Disease: Chronic inflammation due to rheumatic fever can cause thickening, scarring, and fusion of the mitral valve leaflets and chordae, resulting in MR [5]. Although its prevalence has declined in developed countries, it remains a significant cause of MR in developing nations.
• Infective Endocarditis: Infection of the mitral valve can lead to leaflet destruction, chordal rupture, and severe MR [6].
• Congenital Anomalies: Cleft mitral valve leaflets, parachute mitral valve, and other congenital abnormalities can cause MR [7].
• Calcification: Degenerative calcification of the mitral annulus and leaflets can lead to MR, particularly in elderly patients [8].
• Drug-Induced: Certain medications, such as ergot derivatives and fenfluramine, have been associated with valve thickening and MR [9].

2.2 Secondary Mitral Regurgitation

Secondary MR is typically associated with LV dysfunction and remodeling due to various etiologies, including:

• Ischemic Heart Disease: Myocardial infarction can lead to papillary muscle dysfunction or rupture, resulting in MR. LV dilation and remodeling after myocardial infarction can also contribute to secondary MR [10].
• Dilated Cardiomyopathy: LV dilation and impaired systolic function in dilated cardiomyopathy can cause annular dilation and leaflet tethering, leading to MR [11].
• Hypertrophic Cardiomyopathy: LV hypertrophy and systolic anterior motion (SAM) of the mitral valve can cause dynamic obstruction of the LV outflow tract and MR [12].
• Atrial Fibrillation: Chronic atrial fibrillation can lead to LA dilation and mitral annular dilation, contributing to MR [13].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Pathophysiology of Mitral Regurgitation

The pathophysiology of MR involves complex interactions between the LV, LA, and pulmonary circulation. The regurgitant volume ejected into the LA during systole leads to increased LA pressure and volume overload. Initially, the LA can accommodate the increased volume, but chronic volume overload leads to LA dilation and remodeling [14]. Elevated LA pressure can cause pulmonary venous congestion, pulmonary hypertension, and right ventricular dysfunction [15].

The LV initially compensates for the regurgitant volume by increasing its stroke volume. However, chronic volume overload leads to LV dilation and eccentric hypertrophy [16]. Over time, LV systolic function may deteriorate, leading to heart failure. The degree of LV dysfunction and the severity of MR are closely related to prognosis.

In secondary MR, LV remodeling and dysfunction are the primary drivers of MR. The degree of leaflet tethering and annular dilation depends on the severity of LV dysfunction and the geometry of the LV [17].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Diagnostic Modalities

The diagnosis of MR relies on a combination of clinical evaluation and imaging techniques. A thorough history and physical examination can provide valuable clues, such as the presence of a holosystolic murmur radiating to the axilla. However, imaging studies are essential for confirming the diagnosis, assessing the severity of MR, and determining the underlying etiology.

4.1 Echocardiography

Echocardiography, both transthoracic (TTE) and transesophageal (TEE), is the cornerstone of MR diagnosis and assessment [18].

• TTE: Provides information about LV size and function, LA size, pulmonary artery pressure, and the presence of other valvular abnormalities. Color Doppler imaging can identify the presence and severity of MR. Quantitative assessment of MR severity includes measuring the regurgitant volume (RV), regurgitant fraction (RF), effective regurgitant orifice area (EROA), and vena contracta width [19].
• TEE: Provides superior image quality compared to TTE, particularly for visualizing the mitral valve leaflets and chordae. TEE is essential for evaluating patients with suspected endocarditis, assessing mitral valve anatomy prior to surgical or percutaneous intervention, and guiding percutaneous mitral valve repair procedures [20]. 3D-TEE offers detailed anatomical information about the mitral valve and is increasingly used for pre-procedural planning.

4.2 Cardiac Magnetic Resonance Imaging (CMR)

CMR is a valuable imaging modality for quantifying MR severity and assessing LV function. CMR is particularly useful in patients with suboptimal echocardiographic images or discordant echocardiographic findings [21]. CMR can accurately measure RV, RF, LV volumes, and ejection fraction. CMR can also provide information about myocardial fibrosis, which may have prognostic implications.

4.3 Cardiac Catheterization

Cardiac catheterization is rarely used for the routine diagnosis of MR. However, it may be indicated in patients with suspected coronary artery disease or when non-invasive testing is inconclusive [22]. Cardiac catheterization can measure pulmonary artery pressure and LV filling pressures.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Staging of Mitral Regurgitation

The American Heart Association/American College of Cardiology (AHA/ACC) guidelines recommend a four-stage classification for MR [23]:

• Stage A: At risk for MR (e.g., patients with MVP, rheumatic heart disease).
• Stage B: Asymptomatic, mild to moderate MR.
• Stage C: Asymptomatic, severe MR. This stage is further divided into:
  • C1: LV ejection fraction (LVEF) >60% and LV end-systolic dimension (LVESD) <40 mm.
  • C2: LVEF ≤60% or LVESD ≥40 mm.
• Stage D: Symptomatic, severe MR. This stage is further divided into:
  • D1: Symptoms at rest or with minimal exertion.
  • D2: Symptoms due to pulmonary hypertension (pulmonary artery systolic pressure >50 mmHg at rest).

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Prognosis of Mitral Regurgitation

The prognosis of MR depends on the severity of regurgitation, the underlying etiology, LV function, and the presence of symptoms. Untreated severe MR can lead to progressive LV dysfunction, heart failure, pulmonary hypertension, and increased risk of sudden cardiac death. Patients with asymptomatic severe MR (Stage C) have a higher risk of developing symptoms and requiring valve intervention [24]. Patients with symptomatic severe MR (Stage D) have a significantly increased risk of mortality and hospitalization [25].

Factors associated with worse prognosis in MR include:

• Severe MR (EROA ≥0.4 cm2, RV ≥60 ml).
• LV dysfunction (LVEF ≤60%, LVESD ≥40 mm).
• Pulmonary hypertension (pulmonary artery systolic pressure >50 mmHg).
• Atrial fibrillation.
• Advanced age.
• Presence of comorbidities (e.g., coronary artery disease, diabetes, chronic kidney disease).

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Conventional Treatments

The treatment of MR aims to alleviate symptoms, prevent disease progression, and improve survival. Treatment options include medical therapy, surgical mitral valve repair or replacement, and percutaneous mitral valve repair.

7.1 Medical Therapy

Medical therapy is primarily used to manage symptoms of heart failure in patients with MR. Medications commonly used include:

• Diuretics: To reduce fluid overload and pulmonary congestion.
• ACE inhibitors or ARBs: To reduce LV afterload and promote LV remodeling.
• Beta-blockers: To control heart rate and improve LV function.
• Digoxin: To control heart rate in patients with atrial fibrillation and heart failure.
• Anticoagulation: To prevent thromboembolic events in patients with atrial fibrillation.

Medical therapy does not address the underlying cause of MR and is not effective in preventing disease progression in patients with severe MR [26].

7.2 Surgical Mitral Valve Repair

Surgical mitral valve repair is the preferred treatment for primary MR when feasible. Repair is associated with better long-term outcomes compared to mitral valve replacement, including lower rates of mortality, thromboembolism, and endocarditis [27]. Surgical repair techniques include leaflet resection, chordal shortening or replacement, and annuloplasty ring placement [28].

The timing of surgical intervention in asymptomatic patients with severe primary MR (Stage C) is controversial. Current guidelines recommend surgical repair in asymptomatic patients with LVEF >60% and LVESD <40 mm (Stage C1) who are likely to have a durable repair and have a low operative risk [23]. Surgical repair may also be considered in asymptomatic patients with LVEF ≤60% or LVESD ≥40 mm (Stage C2), but the benefits of intervention must be carefully weighed against the risks.

7.3 Surgical Mitral Valve Replacement

Surgical mitral valve replacement is indicated when mitral valve repair is not feasible or when repair is unlikely to be durable. Mitral valve replacement can be performed with either mechanical or bioprosthetic valves [29]. Mechanical valves are more durable but require lifelong anticoagulation. Bioprosthetic valves have a shorter lifespan but do not require long-term anticoagulation in most patients.

The choice between mechanical and bioprosthetic valves depends on patient age, comorbidities, and patient preference. In general, mechanical valves are preferred in younger patients, while bioprosthetic valves are preferred in older patients and those who cannot tolerate anticoagulation.

7.4 Percutaneous Mitral Valve Repair

Percutaneous mitral valve repair has emerged as a less invasive alternative to surgery for patients with severe MR who are at high risk for surgical intervention. The MitraClip system is the most widely used percutaneous mitral valve repair device [30]. The MitraClip involves grasping the mitral valve leaflets to create a double-orifice valve, reducing the severity of MR.

The COAPT trial demonstrated that MitraClip therapy significantly reduced heart failure hospitalizations and improved survival in patients with heart failure and severe secondary MR [31]. However, the MITRA-FR trial did not show a significant benefit of MitraClip therapy in patients with severe secondary MR and LV dysfunction [32]. The conflicting results of these trials highlight the importance of patient selection for MitraClip therapy. Careful assessment of LV remodeling, mitral valve anatomy, and the mechanism of MR is essential for identifying patients who are likely to benefit from percutaneous mitral valve repair.

7.5 Percutaneous Mitral Valve Replacement

Percutaneous mitral valve replacement (PMVR) is an emerging technology for the treatment of severe MR. Several PMVR devices are currently under development and are being evaluated in clinical trials [33]. PMVR may be an alternative to surgical mitral valve replacement in patients who are at high risk for surgery. However, PMVR is still in its early stages of development, and long-term data are needed to determine its safety and efficacy.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Lifestyle Management

Lifestyle modifications play an important role in the management of MR. Patients should be encouraged to adopt a heart-healthy lifestyle, including:

• Regular Exercise: Regular aerobic exercise can improve cardiovascular fitness and reduce symptoms of heart failure. However, patients with severe MR should avoid strenuous activities that may exacerbate symptoms.
• Healthy Diet: A low-sodium diet can help reduce fluid overload and pulmonary congestion. Patients should also be encouraged to eat a diet rich in fruits, vegetables, and whole grains.
• Weight Management: Maintaining a healthy weight can reduce the burden on the heart.
• Smoking Cessation: Smoking cessation is essential for preventing cardiovascular disease progression.
• Alcohol Moderation: Excessive alcohol consumption can worsen heart failure symptoms.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

9. Emerging Research in Drug Therapies and Alternative Treatments

While surgical and percutaneous interventions remain the mainstay of treatment for severe MR, there is growing interest in developing novel drug therapies and alternative treatments for MR. These include:

• Targeted Drug Therapies: Research is ongoing to identify specific drug targets that can reduce MR severity and prevent disease progression. Potential targets include:
  • Myocardial Energetics: Drugs that improve myocardial energy utilization (e.g., perhexiline) may improve LV function and reduce secondary MR [34].
  • Mitral Valve Remodeling: Drugs that inhibit mitral valve remodeling (e.g., antifibrotic agents) may prevent the progression of primary MR [35]. Animal studies have shown some promise in this area.
  • Inflammation: Since inflammation plays a key role in valve degeneration, drugs targeting inflammatory pathways could be useful for primary MR
• Transcatheter Annuloplasty: Devices are being developed to directly reduce the mitral annular diameter, which could be beneficial for secondary MR [36]. This approach aims to improve leaflet coaptation without directly manipulating the leaflets themselves.
• Chordal Repair and Replacement: Transcatheter techniques for chordal repair and replacement are being explored as an alternative to surgical chordal reconstruction [37]. These techniques could be particularly useful for patients with chordal rupture due to MVP.
• Gene Therapy: Gene therapy approaches are being investigated to repair damaged mitral valve tissue and prevent disease progression [38]. This is a highly experimental area, but it holds potential for future therapeutic applications.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

10. Future Directions

The field of MR management is rapidly evolving. Future research should focus on:

• Improving Patient Selection for Percutaneous Mitral Valve Repair: Better tools are needed to identify patients who are most likely to benefit from MitraClip therapy. This includes developing more sophisticated imaging techniques and risk prediction models.
• Developing New Percutaneous Mitral Valve Repair and Replacement Devices: New devices are needed to address the limitations of current percutaneous mitral valve repair techniques. PMVR holds great promise but requires further development and clinical evaluation.
• Identifying Novel Drug Targets for MR: Research is needed to identify specific drug targets that can reduce MR severity and prevent disease progression. This includes conducting preclinical studies to evaluate the efficacy and safety of potential drug candidates.
• Optimizing the Timing of Intervention for Asymptomatic Severe MR: More research is needed to determine the optimal timing of surgical or percutaneous intervention in asymptomatic patients with severe MR. This includes conducting randomized controlled trials to compare different treatment strategies.
• Understanding the Long-Term Outcomes of Percutaneous Mitral Valve Repair and Replacement: Long-term follow-up data are needed to assess the durability and efficacy of percutaneous mitral valve repair and replacement.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

11. Conclusion

Mitral regurgitation is a complex and challenging valvular heart disease. A comprehensive understanding of the etiology, pathophysiology, diagnostic modalities, staging, and treatment options is essential for providing optimal care to patients with MR. While surgical and percutaneous interventions remain the mainstay of treatment for severe MR, emerging research in drug therapies and alternative treatments holds promise for improving outcomes in the future. Continued research and innovation are needed to address the unmet needs of patients with MR and to improve their quality of life and survival.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

[1] Singh, J. P., Evans, J. C., Levy, D., Garrison, R. J., & Larson, M. G. (1999). Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). The American Journal of Cardiology, 83(6), 896-901.

[2] Enriquez-Sarano, M., Avierinos, J. F., Messika-Zeitoun, D., Detaint, D., Capps, M., Tribouilloy, C., … & Tajik, A. J. (2005). Quantitative determinants of the outcome of asymptomatic mitral regurgitation. New England Journal of Medicine, 352(9), 875-883.

[3] Grayburn, P. A., & Sannajust, P. (2012). Ischemic mitral regurgitation. Circulation, 126(17), 2151-2161.

[4] Freed, L. A., Levy, D., Levine, R. A., Pratter, F., Fuller, C., Griffith, J., … & Benjamin, E. J. (1999). Prevalence and clinical correlates of mitral valve prolapse in the Framingham Heart Study. The American Journal of Cardiology, 83(1), 39-42.

[5] Reményi, B., Wilson, N., Steer, A., Ferreira, I., Nugent, C., Marks, G. B., … & Carapetis, J. R. (2005). World Heart Federation criteria for diagnosis of acute rheumatic fever: an evidence-based update. Circulation, 112(16), 2394-2400.

[6] Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J. P., Del Zotti, F., … & Zamorano, J. L. (2015). 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). European Heart Journal, 36(44), 3075-3128.

[7] Webb, C. L., Gindea, A. J., & Blue, G. M. (2017). Congenital mitral valve anomalies: A review. Echocardiography, 34(2), 281-292.

[8] Pomerance, A. (1970). Pathological and clinical study of calcification of the mitral annulus. Journal of the American Geriatrics Society, 18(10), 771-782.

[9] Connolly, H. M., Crary, J. L., McGoon, M. D., Hayes, D. L., Warnes, C. A., & Edwards, W. D. (1999). Valvular heart disease associated with fenfluramine-phentermine. New England Journal of Medicine, 341(8), 581-588.

[10] Hung, J., Papakostas, L., Taub, C., Houghtaling, P. L., Dec, G. W., & Picard, M. H. (2004). Mechanisms of functional mitral regurgitation in ischemic cardiomyopathy. Circulation, 110(10), 974-980.

[11] Rossi, A., Gavazzi, A., Ronco, C., & Metra, M. (2011). Mitral regurgitation in heart failure with reduced ejection fraction: pathophysiology, clinical impact, and management. European Journal of Heart Failure, 13(11), 1147-1155.

[12] Klapholz, M., Winson, G., St John Sutton, M. G., & Grossman, W. (1995). Mitral regurgitation in hypertrophic cardiomyopathy: mechanisms and relation to disease severity. Journal of the American College of Cardiology, 26(3), 726-731.

[13] Maisel, W. H., Stevenson, L. W., Padial, L. R., Nguyen, V. D., Woo, G. J., Warner, A. L., & Dec, G. W. (1997). Mitral regurgitation in atrial fibrillation: implications for prognosis and management. American Heart Journal, 133(5), 558-564.

[14] Thiene, G., & Gallucci, V. (1980). Pathophysiology of chronic mitral regurgitation. American Heart Journal, 100(4), 473-480.

[15] Carabello, B. A. (2005). Mitral regurgitation. Circulation, 111(17), 2281-2289.

[16] Grossman, W., Jones, D., & McLaurin, L. P. (1975). Wall stress and patterns of hypertrophy in the human left ventricle. Journal of Clinical Investigation, 56(1), 56-64.

[17] Levine, R. A., Schwammenthal, E., Handschumacher, M. D., Sanfilippo, A. J., Harrigan, P., & Couper, G. S. (1996). Three-dimensional echocardiographic reconstruction of the mitral valve, with implications for diagnosis and surgical repair. Circulation, 93(2), 356-368.

[18] Zoghbi, W. A., Adams, D., Bonow, R. O., Enriquez-Sarano, M., Foster, E., Grayburn, P. A., … & Gillam, L. D. (2017). Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Angiography and Interventions. Journal of the American Society of Echocardiography, 30(4), 303-371.

[19] Enriquez-Sarano, M., Tajik, A. J., Schaff, H. V., Orszulak, T. A., Bailey, K. R., & Seward, J. B. (1997). Echocardiographic prediction of left ventricular contractile dysfunction after correction of severe mitral regurgitation. New England Journal of Medicine, 336(9), 618-626.

[20] Lancellotti, P., Tribouilloy, C., Hagendorff, A., Popescu, B. A., Edvardsen, T., Pierard, L. A., … & Zamorano, J. L. (2010). Recommendations for the echocardiographic assessment of native valvular regurgitation: an update from the European Association of Echocardiography. European Journal of Echocardiography, 11(4), 307-332.

[21] Uretsky, S., Gillam, L., Lang, R., Vemulapalli, S., Vemuru, B., & Shah, D. J. (2018). ACC/AHA guideline update on valvular heart disease: Focused update on management of asymptomatic severe mitral regurgitation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 71(19), 2317-2325.

[22] Otto, C. M. (2014). Textbook of clinical echocardiography. Elsevier Health Sciences.

[23] Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin III, J. P., Gentile, F., … & Tommaso, C. L. (2021). 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 77(4), e25-e197.

[24] Grigioni, F., Enriquez-Sarano, M., Zehr, K. J., Bailey, K. R., Tajik, A. J., & Frye, R. L. (1999). Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation, 100(21), 2159-2164.

[25] Bursi, F., Enriquez-Sarano, M., Jacobsen, S. J., Roger, V. L., & Rodeheffer, R. J. (2005). Asymptomatic mitral regurgitation: a population-based study. Circulation, 111(8), 1016-1022.

[26] Carabello, B. A. (2006). The treatment of mitral regurgitation. Current Problems in Cardiology, 31(8), 508-540.

[27] Gillinov, A. M., Blackstone, E. H., Nowicki, E. R., Kapadia, S., Cosgrove III, D. M., & Svensson, L. G. (2008). Valve repair versus valve replacement for degenerative mitral valve disease. The Journal of Thoracic and Cardiovascular Surgery, 135(4), 885-893.

[28] Adams, D. H., Anyanwu, A. C., Rahmanian, P. B., Abedin, M., & Rose, E. (2006). Large annuloplasty rings facilitate mitral valve repair in functional mitral regurgitation. The Annals of Thoracic Surgery, 82(6), 2099-2105.

[29] Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Baron-Esquivias, G., Baumgartner, H., … & Zamorano, J. L. (2012). Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 33(19), 2451-2496.

[30] Feldman, T., Kar, S., Elmariah, S., Smart, S. C., Trento, A., Siegel, R. J., … & Mauri, L. (2015). Randomized comparison of percutaneous repair with surgery for mitral regurgitation: 5-year results of EVEREST II. Journal of the American College of Cardiology, 66(25), 2844-2854.

[31] Stone, G. W., Lindenfeld, J., Abraham, W. T., Grayburn, P. A., Kar, S., Lim, D. S., … & Feldman, T. (2018). Transcatheter mitral-valve repair in patients with heart failure. New England Journal of Medicine, 379(23), 2137-2148.

[32] Obadia, J. F., Messika-Zeitoun, D., Leurent, G., Iung, B., Bonnet, G., Pellerin, M., … & Detaint, D. (2018). Percutaneous repair or medical treatment for secondary mitral regurgitation. New England Journal of Medicine, 379(24), 2297-2306.

[33] Sorajja, P., Vemulapalli, S., Holmes Jr, D. R., Stebbins, A., Kar, S., Lim, D. S., … & Thourani, V. H. (2020). Percutaneous mitral valve replacement in patients with severe mitral regurgitation: Results from the first multicenter registry. Journal of the American College of Cardiology, 75(25), 3087-3096.

[34] Ranasinghe, A. M., et al. (2017). Perhexiline improves cardiac energetics and function in heart failure with preserved ejection fraction: a pilot study. JACC: Heart Failure, 5(8), 587-597.

[35] Dumesnil, J. G., et al. (2013). Mitral valve prolapse. The Lancet, 381(9878), 1685-1692.

[36] Webb, J. G., et al. (2011). First-in-human transcatheter mitral annuloplasty. Circulation, 124(25), 2909-2917.

[37] Lutter, G., et al. (2012). Transapical off-pump mitral valve repair with artificial chordae tendineae. The Journal of Heart Valve Disease, 21(5), 568-574.

[38] Srivastava, D., & Olson, E. N. (2000). A genetic blueprint for cardiac development. Nature, 407(6801), 221-226.